- Tempero, Margaret;
- Ko, Andrew;
- Ko, AH;
- Shan, YS;
- Su, WC;
- Lin, YL;
- Dito, E;
- Ong, A;
- Wang, YW;
- Yeh, CG;
- Chen, LT
Background: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer. Met
